Skip to content
Dibucaine
Heavy Solution Nupercaine (dibucaine) is a small molecule pharmaceutical. Dibucaine was first approved as Heavy solution nupercaine on 1982-01-01. It is used to treat irritant dermatitis, pain, pruritus, and sunburn in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
wounds and injuriesD014947
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dibucaine hydrochloride
Tradename
Company
Number
Date
Products
HEAVY SOLUTION NUPERCAINENovartisN-006203 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dibucaineOTC monograph final2023-05-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
irritant dermatitisD017453L24
painEFO_0003843D010146R52
pruritusHP_0000989D011537L29
sunburnEFO_0003958D013471L55
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C05: Vasoprotectives
C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
C05AD: Local anesthetics for treatment of hemorrhoids and anal fissures for topical use
C05AD04: Cinchocaine
D: Dermatologicals
D04: Antipruritics, incl. antihistamines, anesthetics, etc.
D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
D04AB: Anesthetics for topical use
D04AB02: Cinchocaine
N: Nervous system drugs
N01: Anesthetics
N01B: Local anesthetics
N01BB: Amide local anesthetics
N01BB06: Cinchocaine
S: Sensory organ drugs
S01: Ophthalmologicals
S01H: Local anesthetics, ophthalmologic
S01HA: Local anesthetics
S01HA06: Cinchocaine
S02: Otologicals
S02D: Other otologicals in atc
S02DA: Analgesics and anesthetics
S02DA04: Cinchocaine
HCPCS
No data
Clinical
Clinical Trials
139 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypothyroidismD007037EFO_0004705E03.9183182553
Healthy volunteers/patients111213
Thyroid diseasesD013959HP_0000820E00-E072237
Thyroid neoplasmsD013964EFO_000384111136
Congenital hypothyroidismD003409E00.1235
Graves diseaseD006111EFO_0004237E05.01224
Heart failureD006333EFO_0003144I50134
Myocardial infarctionD009203EFO_0000612I211113
Endocrine system diseasesD004700EFO_0001379E34.9123
Down syndromeD004314EFO_0001064Q90112
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.1134
HyperthyroxinemiaD006981EFO_0004127213
Cardiovascular diseasesD002318EFO_0000319I98112
Coronary diseaseD003327112
Myocardial ischemiaD017202EFO_1001375I20-I25112
Heart diseasesD006331EFO_0003777I51.9112
Brain deathD001926G93.82112
Chronic renal insufficiencyD051436N18112
DyslipidemiasD050171HP_0003119112
Cerebral intraventricular hemorrhageD00007404211
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autoimmune thyroiditisD013967EFO_0006812E06.3123
InfertilityD007246EFO_0000545112
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8122
Type 2 diabetes mellitusD003924EFO_0001360E1111
Liver cirrhosisD008103EFO_0001422K74.011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD01059922
Drug interactionsD00434711
Iron-deficiency anemiaD018798HP_0001891D5011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperthyroidismD006980E05.922
Diabetes mellitusD003920EFO_0000400E08-E1311
Renal dialysisD006435EFO_0010690Z99.211
ObesityD009765EFO_0001073E66.911
Morbid obesityD009767EFO_000107411
Pregnancy rateD01887311
AgingD000375GO_0007568R41.8111
Food-drug interactionsD01856511
Head and neck neoplasmsD00625811
Laryngeal neoplasmsD007822EFO_0003817C3211
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIBUCAINE
INNcinchocaine
Description
Cinchocaine is a monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions. It has a role as a topical anaesthetic. It is a monocarboxylic acid amide, a tertiary amino compound and an aromatic ether.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1
Identifiers
PDB
CAS-ID85-79-0
RxCUI3339
ChEMBL IDCHEMBL1086
ChEBI ID247956
PubChem CID3025
DrugBankDB00527
UNII IDL6JW2TJG99 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,415 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4 adverse events reported
View more details